Clinical trials: Fecal Microbiota Therapy (FMT)
Obesity
Fecal Microbiota Transplantation for the Treatment of Obesity
This is a randomized controlled pilot study to assess the microbiological and clinical impacts of Fecal Microbiota Transplantation (FMT) in patients with obesity.
- Trial name
- FMT Obesity (NCT02741518)
- Testing
- Fecal Microbiota Transplantation
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Brigham and Women's Hospital
Clostridioides Difficile Infection
Clostridioides Difficile: Understanding Responses and Treatment Effects
The goal of this observational study is to learn how different treatments for Clostridioides difficile infection (CDI) work, and which biological mechanisms are involved in recovery.
- Trial name
- CURE-CDI (NCT07374094)
- Testing
- Antibiotic treatment, Fecal microbiota transplantation (FMT)
- Where
- Sweden
- Volunteers
- 200 people
- Sponsor
- Umeå University
Clostridium Difficile Infection
Fecal Microbiota Transplant for Primary CDI
Clostridium difficile infection (CDI) is one of the most urgent health threats in the U.S. associated with antibiotic use. After an initial episode, disease recurrence is high and relapses can occur in 20-30% of people treated…
- Trial name
- NCT03795233
- Testing
- Fecal microbiota transplant G3 capsules, Oral Vancomycin alone
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Boston Medical Center
Obesity; Familial
Assessment of the Health Improvement of Obese Patients After Fecal Microbiota Transplantation (FMT)
Search for mechanisms of the effect of fecal microbiota transplantation on patients with obesity
- Trial name
- NCT04579263
- Testing
- Fecal microbiota
- Where
- 2 sites in Russia
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Federal Research and Clinical Center of Physical-Chemical Medicine
Ulcerative Colitis
Clinical Study on the Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis With Depression
This is a single-center trial, randomized, single-blind, placebo-controlled clinical intervention study which intends to explore the safety and effectiveness of FMT capsule for the treatment of ulcerative colitis with depression.
- Trial name
- NCT05030064
- Testing
- Intestinal flora capsule
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Third Military Medical University
Metastatic Colorectal Adenocarcinoma, Metastatic Small Intestinal Adenocarcinoma
Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
This phase II trial studies the effect of fecal microbiota transplant and re-introduction of anti-PD-1 therapy (pembrolizumab or nivolumab) in treating anti-PD-1 non-responders with colorectal cancer that has spread to other…
- Conditions
- Metastatic Colorectal Adenocarcinoma, Metastatic Small Intestinal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8
- Trial name
- NCT04729322
- Testing
- Biopsy, Fecal Microbiota Transplantation, Fecal Microbiota Transplantation Capsule
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Ulcerative Colitis
Fecal Microbiota Transplantation (FMT) for Treatment of Ulcerative Colitis in Children
Patients diagnosed with ulcerative colitis (UC), a specific type of inflammatory bowel disease, will be invited to take part in this study. The investigators do not know what causes UC.
- Trial name
- FMT (NCT01947101)
- Testing
- Fecal Microbiota Transplant
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
HIV Infections
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
Patients eligible for the study will be selected on Fridays during the HIV consultation at the Infectious Diseases Department. Patients that meet the inclusion and exclusion criteria, will be randomized and assigned in two groups…
- Trial name
- NCT04165200
- Testing
- Blood and feces samples
- Where
- Mexico
- Volunteers
- 22 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Kidney Stones, Urinary Stone Disease / Nephrolithiasis
Fecal Microbiota Transplantation in Kidney Stone Patients
This open-label pilot study evaluates whether oral microbial transplant therapy can change urine factors associated with recurrent calcium-oxalate kidney stones.
- Conditions
- Kidney Stones, Urinary Stone Disease / Nephrolithiasis, Recurrent Calcium-oxalate Kidney Stones
- Trial name
- FMT IND (NCT05516472)
- Testing
- Microbial Transplant Therapy (FMT CAPSULE DE / FMPCapDE / MTP-CP101), Vancomycin and neomycin antibiotic pretreatment
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Joshua Stern
Intestinal Graft Versus Host Disease
Fecal Microbiota Transplant and Dietary Fiber Supplementation for the Treatment of Gut Graft Versus Host Disease
This phase I trial studies how well fecal microbiota transplant and dietary fiber supplementation work in treating patients with gut graft versus host disease.
- Trial name
- NCT05067595
- Testing
- Colonoscopy, Fecal Microbiota Transplantation, Nutritional Supplementation
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Fred Hutchinson Cancer Center
Clostridium Difficile Infection
Treatment of C. Difficile Infection With Fecal Microbiota Transplantation (FMT)
The purpose of this study is to treat children with severe, moderate, resistant or relapsing C. difficile infection and to determine the changes in the intestinal microbiome (all of the bacteria living in the intestines) in…
- Trial name
- NCT01842347
- Testing
- Fecal microbiota
- Where
- United States
- Sponsor
- Medical College of Wisconsin
Severe Alcoholic Hepatitis
A Comparison of Fecal Microbiota Transplantation and Steroid Therapy in Patients With Severe Alcoholic Hepatitis.
Study population: Patients attending the Out Patient Department and admitted to Institute of Liver and Biliary Sciences. Study design: Prospective randomized controlled trial Study period: One year- January 2017- December 2018…
- Trial name
- NCT03091010
- Testing
- Fecal Microbiota Transplantation, Steroids
- Where
- India
- Volunteers
- 112 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
HIV-1-infection
Safety of FMT Using Oral Encapsulated PRIM-DJ2727 in HIV
The purpose of this study is to determine whether oral fecal microbiota transplantation (FMT) is safe for people with human immunodeficiency virus (HIV) infection.
- Trial name
- NCT03329560
- Testing
- Oral fecal microbiota transplantation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- The University of Texas Health Science Center, Houston
Schizophrenia
A Study of the Efficacy of Fecal Microbiota Transplantation(FMT) in the Treatment of Schizophrenia
The purpose of this study was to explore whether repeated oral fecal capsules could improve outcomes in patients with schizophrenia receiving conventional antipsychotic drugs.
- Trial name
- NCT05850585
- Testing
- Fecal microbiota transplantation(FMT)
- Volunteers
- 100 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Chronic Intestinal Pseudo Obstruction
Efficacy and Safety of Fecal Microbiota Transplantation for Chronic Intestinal Pseudo-obstruction
Chronic intestinal pseudo obstruction(CIPO) is a serious motility disorder with life-threatening condition, and it is often related with bacterial overgrowth.
- Trial name
- NCT02731183
- Testing
- fecal microbiota transplantation
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Jinling Hospital, China
Irritable Bowel Syndrome (IBS)
Safety and Efficacy of Lyophilized Faecal Microbiota Transplantation Via Capsules in Treatment of Irritable Bowel Syndrome
The goal of this clinical trial is to learn if oral capsules containing lyophilized fecal microbiota transplantation (FMT) can safely and effectively treat refractory irritable bowel syndrome (IBS) in adults aged 18-65 years.
- Trial name
- LYO-IBS (NCT07481422)
- Testing
- FMT capsule
- Where
- Croatia
- Volunteers
- 70 people
- Sponsor
- University of Rijeka
Solid Carcinoma
FMT With Nivolumab in Patients With Advanced Solid Cancers Who Have Progressed During Anti-PD-(L)1 Therapy
This is a single-center, open-label, Phase 2 study to evaluate the efficacy and safety of FMT with nivolumab in patients with advanced, unresectable, or metastatic solid cancer who have progressed during anti-PD-(L)1 therapy.
- Trial name
- NIVO-FMT (NCT05533983)
- Testing
- fecal microbiota transplantation with Nivolumab
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Asan Medical Center
Acute Graft Versus Host Disease, Gastrointestinal Tract Acute Graft Versus Host Disease
Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease
This phase I trial studies the side effects of using an investigational procedure (fecal microbiota transplantation [FMT]) in treating patients with severe acute gut graft-versus-host-disease.
- Conditions
- Acute Graft Versus Host Disease, Gastrointestinal Tract Acute Graft Versus Host Disease, Severe Gastrointestinal Tract Acute Graft Versus Host Disease, Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host Disease
- Trial name
- NCT04280471
- Testing
- Fecal Microbiota Transplantation Capsule
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Autism Spectrum Disorder, Gastro-Intestinal Disorder
MTT for Children With ASD Who Have Gastrointestinal Disorders
The investigators propose to investigate Microbiota Transfer Therapy (MTT) for treating children with Autism Spectrum Disorder (ASD) and gastrointestinal problems (primarily constipation and/or diarrhea).
- Conditions
- Autism Spectrum Disorder, Gastro-Intestinal Disorder, Constipation, Diarrhea
- Trial name
- NCT04182633
- Testing
- vancomycin, Miralax, intestinal microbiota
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Arizona State University
Clostridium Difficile Infection Recurrence
Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff
Subjects with recurrent C. difficile infection will receive an oral dose of CP101 capsules one time in Treatment Group I or matching placebo one time in Treatment Group II.
- Trial name
- PRISM3 (NCT03110133)
- Testing
- Full Spectrum Microbiota
- Where
- 58 sites in United States, Canada
- Volunteers
- 206 people
- Sponsor
- Finch Research and Development LLC.